Metraipolis › archive › dc_2febb6fd6264

A long noncoding RNA-based serum signature predicts ado-trastuzumab emtansine (T-DM1) treatment benefit in HER2+ metastatic breast cancer patients: a… — Europe PMC PMID:40925917

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40925917
DOI
10.1038/s41420-[numero omesso]-8
License (as archived)
solo-consultazione
Archived
2026-11-10T01:29:21.151Z
SHA-256 of the archived text
9d016dc7c609e97f157b01a526dacd028c7fc4025011f3c250399c111368ea8f
Stable URL of this page
https://metraipolis.com/documento/dc_2febb6fd6264

How to cite

A long noncoding RNA-based serum signature predicts ado-trastuzumab emtansine (T-DM1) treatment benefit in HER2+ metastatic breast cancer patients: a… — Europe PMC PMID:40925917 — Europe PMC (en), https://europepmc.org/article/MED/40925917 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2febb6fd6264 (Metraipolis archive dc_2febb6fd6264, sha256 9d016dc7c609e97f157b01a526dacd028c7fc4025011f3c250399c111368ea8f)
BibTeX
@misc{dc2febb6fd6264,
  title = {A long noncoding RNA-based serum signature predicts ado-trastuzumab emtansine (T-DM1) treatment benefit in HER2+ metastatic breast cancer patients: a… — Europe PMC PMID:40925917},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40925917},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2febb6fd6264; sha256 9d016dc7c609e97f157b01a526dacd028c7fc4025011f3c250399c111368ea8f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40925917. Agents can read the archived copy with the MCP tool read_document.